Vancouver Prostate Centre investigators were highly successful, receiving 6 Canadian Institutes of Health Research (CIHR) research grants in the Fall 2017 Project Grant competition for a total of $3.48 million over five years.
The funded projects are:
- Ralph Buttyan (co-Is: Artem Cherkasov, Nathan Lack, Na Li): Interference with Gli to Control Castration Resistant Prostate Cancer. 3 years. $344,250
- Artem Cherkasov (co-Is: Paul Rennie, Kush Dalal; Collaborator: Natalie Strynadka): Design and evaluation of small molecules that target the dimerization interface of full-length and splice-variant forms of the androgen receptor as a potential treatment for advanced prostate cancer. 3 years. $600,000
- Mads Daugaard & William Derry (Hospital for Sick Children, Toronto): Role of alternative polyadenylation in Ras-driven cancers. 5 years. $1,113,075
- Xuesen Dong: RNA splicing regulates prostate cancer progression to hormone therapy resistant neuroendocrine tumors. 5 years. $699,975
- Martin Gleave & Nathan Lack (co-Is: Artem Cherkasov, Paul Rennie, Robert Young): Preclinical development of a novel androgen receptor antagonist to treat castration-resistant prostate cancer. Commercialization Project Grant. 2 years. $351,900
- Alex Wyatt & Kim Chi: Predicting therapy resistance in castration-resistant prostate cancer with circulating tumor DNA. 3 years. $516,375